{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:08:23Z","timestamp":1787242103943,"version":"build-2736575974"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T00:00:00Z","timestamp":1553212800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13256-019-2013-z","type":"journal-article","created":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T21:02:12Z","timestamp":1553202132000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Three different polymorphisms of the DPYD gene associated with severe toxicity following administration of 5-FU: a\u00a0case report"],"prefix":"10.1186","volume":"13","author":[{"given":"Deborah","family":"Mukherji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Abdel","family":"Massih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arafat","family":"Tfayli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Kanso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid","family":"Faraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,22]]},"reference":[{"issue":"3","key":"2013_CR1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3816\/CCC.2004.n.018","volume":"4","author":"H Ezzeldin","year":"2004","unstructured":"Ezzeldin H, Diasio R. Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. Clin Colorectal Cancer. 2004;4(3):181\u20139.","journal-title":"Clin Colorectal Cancer"},{"issue":"3","key":"2013_CR2","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1200\/JCO.2015.63.1325","volume":"34","author":"MJ Deenen","year":"2016","unstructured":"Deenen MJ, et al. Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis. J Clin Oncol. 2016;34(3):227\u201334.","journal-title":"J Clin Oncol"},{"issue":"12","key":"2013_CR3","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1038\/bjc.2013.262","volume":"108","author":"A Loganayagam","year":"2013","unstructured":"Loganayagam A, et al. Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity. Br J Cancer. 2013;108(12):2505\u201315.","journal-title":"Br J Cancer"},{"issue":"4","key":"2013_CR4","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3816\/CCC.2006.n.047","volume":"6","author":"C Mercier","year":"2006","unstructured":"Mercier C, Ciccolini J. Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil\/capecitabine therapy. Clin Colorectal Cancer. 2006;6(4):288\u201396.","journal-title":"Clin Colorectal Cancer"},{"key":"2013_CR5","volume-title":"Scrip\u2019s World Pharmaceutical News","author":"Scrip\u2019s Cancer Chemotherapy Report","year":"2002","unstructured":"Scrip\u2019s Cancer Chemotherapy Report. Scrip\u2019s World Pharmaceutical News. London: PJB Publications Ltd.; 2002."},{"issue":"1","key":"2013_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/dna.1995.14.1","volume":"14","author":"R Meinsma","year":"1995","unstructured":"Meinsma R, et al. Human polymorphism in drug metabolism: mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uracilurea. DNA Cell Biol. 1995;14(1):1\u20136.","journal-title":"DNA Cell Biol"},{"issue":"11","key":"2013_CR7","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1200\/JCO.1994.12.11.2248","volume":"12","author":"MC Etienne","year":"1994","unstructured":"Etienne MC, et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol. 1994;12(11):2248\u201353.","journal-title":"J Clin Oncol"},{"issue":"16","key":"2013_CR8","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/S1470-2045(15)00360-5","volume":"16","author":"J Ciccolini","year":"2015","unstructured":"Ciccolini J. DPD deficiency in patients treated with fluorouracil. Lancet Oncol. 2015;16(16):1574\u20136.","journal-title":"Lancet Oncol"},{"issue":"2","key":"2013_CR9","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/00008571-200203000-00007","volume":"12","author":"LK Mattison","year":"2002","unstructured":"Mattison LK, Johnson MR, Diasio RB. A comparative analysis of translated dihydropyrimidine dehydrogenase cDNA: conservation of functional domains and relevance to genetic polymorphisms. Pharmacogenetics. 2002;12(2):133\u201344.","journal-title":"Pharmacogenetics"},{"issue":"16","key":"2013_CR10","doi-asserted-by":"crossref","first-page":"5886","DOI":"10.1158\/1078-0432.CCR-04-1784","volume":"11","author":"K Seck","year":"2005","unstructured":"Seck K, et al. Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals. Clin Cancer Res. 2005;11(16):5886\u201392.","journal-title":"Clin Cancer Res"},{"key":"2013_CR11","first-page":"827989","volume":"2014","author":"Q Li","year":"2014","unstructured":"Li Q, et al. Influence of DPYD genetic polymorphisms on 5-fluorouracil toxicities in patients with colorectal cancer: a meta-analysis. Gastroenterol Res Pract. 2014;2014:827989.","journal-title":"Gastroenterol Res Pract"},{"issue":"7","key":"2013_CR12","doi-asserted-by":"crossref","first-page":"894","DOI":"10.7150\/ijms.5556","volume":"10","author":"X Zhang","year":"2013","unstructured":"Zhang X, Sun B, Lu Z. Evaluation of clinical value of single nucleotide polymorphisms of dihydropyrimidine dehydrogenase gene to predict 5-fluorouracil toxicity in 60 colorectal cancer patients in China. Int J Med Sci. 2013;10(7):894\u2013902.","journal-title":"Int J Med Sci"},{"issue":"5","key":"2013_CR13","first-page":"1149","volume":"7","author":"AB Kuilenburg van","year":"2001","unstructured":"van Kuilenburg AB, et al. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency. Clin Cancer Res. 2001;7(5):1149\u201353.","journal-title":"Clin Cancer Res"},{"issue":"6b","key":"2013_CR14","first-page":"3899","volume":"27","author":"A Uzunkoy","year":"2007","unstructured":"Uzunkoy A, et al. Investigation of IVS14+1G>A polymorphism of DPYD gene in a group of Turkish patients with colorectal cancer. Anticancer Res. 2007;27(6b):3899\u2013902.","journal-title":"Anticancer Res"},{"issue":"11","key":"2013_CR15","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2217\/pgs.13.116","volume":"14","author":"S Terrazzino","year":"2013","unstructured":"Terrazzino S, et al. DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis. Pharmacogenomics. 2013;14(11):1255\u201372.","journal-title":"Pharmacogenomics"},{"issue":"16","key":"2013_CR16","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/S1470-2045(15)00286-7","volume":"16","author":"D Meulendijks","year":"2015","unstructured":"Meulendijks D, et al. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A\/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015;16(16):1639\u201350.","journal-title":"Lancet Oncol"},{"issue":"5 Suppl 15","key":"2013_CR17","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1053\/sonc.2002.35524","volume":"29","author":"J Cassidy","year":"2002","unstructured":"Cassidy J, Misset JL. Oxaliplatin-related side effects: characteristics and management. Semin Oncol. 2002;29(5 Suppl 15):11\u201320.","journal-title":"Semin Oncol"},{"issue":"4","key":"2013_CR18","doi-asserted-by":"crossref","first-page":"153","DOI":"10.14712\/18059694.2015.39","volume":"55","author":"A Paulik","year":"2012","unstructured":"Paulik A, Grim J, Filip S. Predictors of irinotecan toxicity and efficacy in treatment of metastatic colorectal cancer. Acta Med (Hradec Kralove). 2012;55(4):153\u20139.","journal-title":"Acta Med (Hradec Kralove)"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-019-2013-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13256-019-2013-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-019-2013-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T20:14:57Z","timestamp":1584735297000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-019-2013-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,22]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["2013"],"URL":"https:\/\/doi.org\/10.1186\/s13256-019-2013-z","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,22]]},"assertion":[{"value":"13 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Single case reports are not reviewed by our ethics committee\/institutional review board (IRB).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"76"}}